No.,Title,Link
1,Enhancement of tripartite synapses as a potential therapeutic strategy for Alzheimer’s disease: a preclinical study in rTg4510 mice,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0530-z
2,Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0525-9
3,Souvenaid in the management of mild cognitive impairment: an expert consensus opinion,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0528-6
4,Prediction of amyloid pathology in cognitively unimpaired individuals using voxel-wise analysis of longitudinal structural brain MRI,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0526-8
5,A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0524-x
6,"Depression, subjective cognitive decline, and the risk of neurocognitive disorders",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0527-7
7,Music and emotion in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0523-y
8,Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0520-1
9,Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0522-z
10,Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0515-y
11,Tau and atrophy: domain-specific relationships with cognition,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0518-8
12,"Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer’s Coordinating Center Uniform Data Set",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0521-0
13,Towards a unified protocol for handling of CSF before β-amyloid measurements,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0517-9
14,Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0516-x
15,"Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0514-z
16,Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0510-3
17,An experimental model of Braak’s pretangle proposal for the origin of Alzheimer’s disease: the role of locus coeruleus in early symptom development,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0511-2
18,Spermidine/spermine-N1-acetyltransferase ablation impacts tauopathy-induced polyamine stress response,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0507-y
19,FDG-PET as an independent biomarker for Alzheimer’s biological diagnosis: a longitudinal study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0512-1
20,Human amyloid-β enriched extracts: evaluation of in vitro and in vivo internalization and molecular characterization,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0513-0
21,Frailty effects on non-demented cognitive trajectories are moderated by sex and Alzheimer’s genetic risk,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0509-9
22,Upregulation of MIF as a defense mechanism and a biomarker of Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0508-x
23,Brain volumes and cortical thickness on MRI in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER),http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0506-z
24,Avoiding methodological bias in studies of amyloid imaging results disclosure,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0495-y
25,Response to “Avoiding Methodological Bias in Studies of Amyloid Imaging Results Disclosure”,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0504-1
26,Anxiety correlates with cortical surface area in subjective cognitive decline: APOE ε4 carriers versus APOE ε4 non-carriers,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0505-0
27,Electrophysiological brain signatures for the classification of subjective cognitive decline: towards an individual detection in the preclinical stages of dementia,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0502-3
28,Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer’s disease: protocol of the BEAT-IT study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0503-2
29,The association of vascular disorders with incident dementia in different age groups,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0496-x
30,Altered microRNAs related to synaptic function as potential plasma biomarkers for Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0501-4
31,Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0500-5
32,"ApoA-I deficiency increases cortical amyloid deposition, cerebral amyloid angiopathy, cortical and hippocampal astrogliosis, and amyloid-associated astrocyte reactivity in APP/PS1 mice",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0497-9
33,Olfactory function is associated with cognitive performance: results from the population-based LIFE-Adult-Study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0494-z
34,Peripheral administration of human recombinant ApoJ/clusterin modulates brain beta-amyloid levels in APP23 mice,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0498-8
35,Segmentation of medial temporal subregions reveals early right-sided involvement in semantic variant PPA,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0489-9
36,Blood amyloid-β oligomerization associated with neurodegeneration of Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0499-7
37,Correction to: Neurexin 3 transmembrane and soluble isoform expression and splicing haplotype are associated with neuron inflammasome and Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0493-0
38,Neuroinflammation and amyloid-beta 40 are associated with reduced serotonin transporter (SERT) activity in a transgenic model of familial Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0491-2
39,"Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer’s disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0492-1
40,Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline (SmartAge)—study protocol for a randomized controlled trial,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0484-1
41,Exposure to fluoride aggravates the impairment in learning and memory and neuropathological lesions in mice carrying the APP/PS1 double-transgenic mutation,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0490-3
42,Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0485-0
43,Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0487-y
44,Risk of suicide and accidental deaths among elderly patients with cognitive impairment,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0488-x
45,Risk of dementia in patients with end-stage renal disease under maintenance dialysis—a nationwide population-based study with consideration of competing risk of mortality,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0486-z
46,Phenocopy syndrome of behavioral variant frontotemporal dementia: a systematic review,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0483-2
47,CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0481-4
48,Neurexin 3 transmembrane and soluble isoform expression and splicing haplotype are associated with neuron inflammasome and Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0475-2
49,Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0478-z
50,"Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0477-0
51,Enhancement of tripartite synapses as a potential therapeutic strategy for Alzheimer’s disease: a preclinical study in rTg4510 mice,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0530-z
52,Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0525-9
53,Souvenaid in the management of mild cognitive impairment: an expert consensus opinion,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0528-6
54,Prediction of amyloid pathology in cognitively unimpaired individuals using voxel-wise analysis of longitudinal structural brain MRI,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0526-8
55,A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0524-x
56,"Depression, subjective cognitive decline, and the risk of neurocognitive disorders",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0527-7
57,Music and emotion in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0523-y
58,Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0520-1
59,Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0522-z
60,Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0515-y
61,Tau and atrophy: domain-specific relationships with cognition,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0518-8
62,"Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer’s Coordinating Center Uniform Data Set",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0521-0
63,Towards a unified protocol for handling of CSF before β-amyloid measurements,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0517-9
64,Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0516-x
65,"Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0514-z
66,Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0510-3
67,An experimental model of Braak’s pretangle proposal for the origin of Alzheimer’s disease: the role of locus coeruleus in early symptom development,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0511-2
68,Spermidine/spermine-N1-acetyltransferase ablation impacts tauopathy-induced polyamine stress response,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0507-y
69,FDG-PET as an independent biomarker for Alzheimer’s biological diagnosis: a longitudinal study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0512-1
70,Human amyloid-β enriched extracts: evaluation of in vitro and in vivo internalization and molecular characterization,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0513-0
71,Frailty effects on non-demented cognitive trajectories are moderated by sex and Alzheimer’s genetic risk,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0509-9
72,Upregulation of MIF as a defense mechanism and a biomarker of Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0508-x
73,Brain volumes and cortical thickness on MRI in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER),http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0506-z
74,Avoiding methodological bias in studies of amyloid imaging results disclosure,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0495-y
75,Response to “Avoiding Methodological Bias in Studies of Amyloid Imaging Results Disclosure”,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0504-1
76,Anxiety correlates with cortical surface area in subjective cognitive decline: APOE ε4 carriers versus APOE ε4 non-carriers,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0505-0
77,Electrophysiological brain signatures for the classification of subjective cognitive decline: towards an individual detection in the preclinical stages of dementia,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0502-3
78,Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer’s disease: protocol of the BEAT-IT study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0503-2
79,The association of vascular disorders with incident dementia in different age groups,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0496-x
80,Altered microRNAs related to synaptic function as potential plasma biomarkers for Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0501-4
81,Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0500-5
82,"ApoA-I deficiency increases cortical amyloid deposition, cerebral amyloid angiopathy, cortical and hippocampal astrogliosis, and amyloid-associated astrocyte reactivity in APP/PS1 mice",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0497-9
83,Olfactory function is associated with cognitive performance: results from the population-based LIFE-Adult-Study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0494-z
84,Peripheral administration of human recombinant ApoJ/clusterin modulates brain beta-amyloid levels in APP23 mice,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0498-8
85,Segmentation of medial temporal subregions reveals early right-sided involvement in semantic variant PPA,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0489-9
86,Blood amyloid-β oligomerization associated with neurodegeneration of Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0499-7
87,Correction to: Neurexin 3 transmembrane and soluble isoform expression and splicing haplotype are associated with neuron inflammasome and Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0493-0
88,Neuroinflammation and amyloid-beta 40 are associated with reduced serotonin transporter (SERT) activity in a transgenic model of familial Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0491-2
89,"Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer’s disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0492-1
90,Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline (SmartAge)—study protocol for a randomized controlled trial,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0484-1
91,Exposure to fluoride aggravates the impairment in learning and memory and neuropathological lesions in mice carrying the APP/PS1 double-transgenic mutation,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0490-3
92,Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0485-0
93,Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0487-y
94,Risk of suicide and accidental deaths among elderly patients with cognitive impairment,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0488-x
95,Risk of dementia in patients with end-stage renal disease under maintenance dialysis—a nationwide population-based study with consideration of competing risk of mortality,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0486-z
96,Phenocopy syndrome of behavioral variant frontotemporal dementia: a systematic review,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0483-2
97,CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0481-4
98,Neurexin 3 transmembrane and soluble isoform expression and splicing haplotype are associated with neuron inflammasome and Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0475-2
99,Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0478-z
100,"Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0477-0
101,Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective validation study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0482-3
102,Reversible predictors of reversion from mild cognitive impairment to normal cognition: a 4-year longitudinal study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0480-5
103,Lewy Body Dementia Association’s Research Centers of Excellence Program: Inaugural Meeting Proceedings,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0476-1
104,"Concepts for brain aging: resistance, resilience, reserve, and compensation",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0479-y
105,Brief cognitive screening instruments for early detection of Alzheimer’s disease: a systematic review,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0474-3
106,Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0473-4
107,Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0472-5
108,"Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer’s disease",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0467-2
109,Striatal amyloid is associated with tauopathy and memory decline in familial Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0468-1
110,Alzheimer’s disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0469-0
111,Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0466-3
112,Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0471-6
113,18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-019-0470-7
114,Spatial patterns of white matter hyperintensities associated with Alzheimer’s disease risk factors in a cognitively healthy middle-aged cohort,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0460-1
115,Prediction models for dementia and neuropathology in the oldest old: the Vantaa 85+ cohort study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0450-3
116,Data-driven prognostic features of cognitive trajectories in patients with amnestic mild cognitive impairments,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0462-z
117,Consecutive sessions of transcranial direct current stimulation do not remediate visual hallucinations in Lewy body dementia: a randomised controlled trial,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0465-9
118,Prevalence of abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0463-y
119,Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysis,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0459-7
120,CHIMERA repetitive mild traumatic brain injury induces chronic behavioural and neuropathological phenotypes in wild-type and APP/PS1 mice,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0461-0
121,Genome-wide analysis of genetic predisposition to Alzheimer’s disease and related sex disparities,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0458-8
122,Measuring instrumental activities of daily living in non-demented elderly: a comparison of the new performance-based Harvard Automated Phone Task with other functional assessments,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0464-x
123,The quest for synergy between physical exercise and cognitive stimulation via exergaming in people with dementia: a randomized controlled trial,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0454-z
124,Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0456-x
125,Alcohol use and dementia: a systematic scoping review,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0453-0
126,Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0457-9
127,Reactions to learning a “not elevated” amyloid PET result in a preclinical Alzheimer’s disease trial,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0452-1
128,The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0451-2
129,Brain and cognitive correlates of subjective cognitive decline-plus features in a population-based cohort,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0449-9
130,Heterogeneity of Alzheimer’s disease: consequence for drug trials?,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0455-y
131,"A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0448-x
132,Correction to: The Toronto cognitive assessment (TorCA): normative data and validation to detect amnestic mild cognitive impairment,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0446-z
133,Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI),http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0444-1
134,Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0445-0
135,SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA),http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0447-y
136,Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer’s disease clinical program,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0443-2
137,Active full-length DNA Aβ42 immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathology,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0441-4
138,"Haemoglobin, magnetic resonance imaging markers and cognition: a subsample of population-based study",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0440-5
139,Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0439-y
140,Secondary prevention of Alzheimer’s dementia: neuroimaging contributions,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0438-z
141,"Analysis of the risk and risk factors for injury in people with and without dementia: a 14-year, retrospective, matched cohort study",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0437-0
142,Variability in metabolic parameters and risk of dementia: a nationwide population-based study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0442-3
143,Functional connectivity in cognitive control networks mitigates the impact of white matter lesions in the elderly,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0434-3
144,"FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0436-1
145,"Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0431-6
146,Exome sequencing in an Italian family with Alzheimer’s disease points to a role for seizure-related gene 6 (SEZ6) rare variant R615H,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0435-2
147,Neurophysiological signals as predictive translational biomarkers for Alzheimer’s disease treatment: effects of donepezil on neuronal network oscillations in TgF344-AD rats,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0433-4
148,Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer’s dementia?,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0430-7
149,Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY),http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0427-2
150,Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0409-4
151,The impact of education on cortical thickness in amyloid-negative subcortical vascular dementia: cognitive reserve hypothesis,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0432-5
152,Study partners: essential collaborators in discovering treatments for Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0425-4
153,MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0428-1
154,Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0426-3
155,Cardiorespiratory fitness attenuates age-associated aggregation of white matter hyperintensities in an at-risk cohort,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0429-0
156,"Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0424-5
157,Vulnerability and resilience to Alzheimer’s disease: early life conditions modulate neuropathology and determine cognitive reserve,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0422-7
158,The impact of transcranial magnetic stimulation on diagnostic confidence in patients with Alzheimer disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0423-6
159,Patterns of cognitive function in middle-aged and elderly Chinese adults—findings from the EMCOA study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0421-8
160,Sex ratio in dementia with Lewy bodies balanced between Alzheimer’s disease and Parkinson’s disease dementia: a cross-sectional study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0417-4
161,Is intracranial volume a suitable proxy for brain reserve?,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0408-5
162,Cognitive composite score association with Alzheimer’s disease plaque and tangle pathology,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0401-z
163,Clinical dementia severity associated with ventricular size is differentially moderated by cognitive reserve in men and women,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0419-2
164,Inter-network connectivity and amyloid-beta linked to cognitive decline in preclinical Alzheimer’s disease: a longitudinal cohort study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0420-9
165,Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0418-3
166,"Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0410-y
167,"Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0415-6
168,Synergistic interaction between APOE and family history of Alzheimer’s disease on cerebral amyloid deposition and glucose metabolism,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0411-x
169,Apathy is associated with faster global cognitive decline and early nursing home admission in dementia with Lewy bodies,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0416-5
170,Cerebrovascular disease influences functional and structural network connectivity in patients with amnestic mild cognitive impairment and Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0413-8
171,IgM response against amyloid-beta in aging: a potential peripheral protective mechanism,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0412-9
172,Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0407-6
173,Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0405-8
174,"Utility of the Dependence Scale in dementia: validity, meaningfulness, and health economic considerations",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0414-7
175,Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0403-x
176,Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0390-y
177,The EMIF-AD PreclinAD study: study design and baseline cohort overview,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0406-7
178,In vivo quantification of neurofibrillary tangles with [18F]MK-6240,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0402-y
179,Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0372-0
180,Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0398-3
181,Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0404-9
182,Retained capacity for perceptual learning of degraded speech in primary progressive aphasia and Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0399-2
183,Human fibroblast and stem cell resource from the Dominantly Inherited Alzheimer Network,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0400-0
184,Single-word comprehension deficits in the nonfluent variant of primary progressive aphasia,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0393-8
185,Discovery and validation of autosomal dominant Alzheimer’s disease mutations,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0392-9
186,Alzheimer disease pathology and the cerebrospinal fluid proteome,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0397-4
187,The Toronto Cognitive Assessment (TorCA): normative data and validation to detect amnestic mild cognitive impairment,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0382-y
188,"The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0396-5
189,"Plasma amyloid-β levels, cerebral atrophy and risk of dementia: a population-based study",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0395-6
190,Modifiable dementia risk score to study heterogeneity in treatment effect of a dementia prevention trial: a post hoc analysis in the preDIVA trial using the LIBRA index,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0389-4
191,Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0386-7
192,Infrequent false positive [18F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0387-6
193,Alzheimer’s disease master regulators analysis: search for potential molecular targets and drug repositioning candidates,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0394-7
194,Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer’s disease and vascular dementia,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0385-8
195,Why could meditation practice help promote mental health and well-being in aging?,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0388-5
196,Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0391-x
197,Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer’s disease and frontotemporal dementia,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0378-7
198,Immunotherapy to improve cognition and reduce pathological species in an Alzheimer’s disease mouse model,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0384-9
199,"“Exceptional brain aging” without Alzheimer’s disease: triggers, accelerators, and the net sum game",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0373-z
200,"Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer’s disease",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0383-x
201,What is the impact of regulatory guidance and expiry of drug patents on dementia drug prescriptions in England? A trend analysis in the Clinical Practice Research Datalink,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0379-6
202,Effects of lifetime cumulative ginseng intake on cognitive function in late life,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0380-0
203,Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0377-8
204,White matter microstructure is altered in cognitively normal middle-aged APOE-ε4 homozygotes,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0375-x
205,Meaning in life: resilience beyond reserve,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0381-z
206,Distinct patterns of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed by visual rating scales,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0376-9
207,Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0374-y
208,A double-blind placebo-controlled cross-over clinical trial of DONepezil In Posterior cortical atrophy due to underlying Alzheimer's Disease: DONIPAD study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0363-1
209,Cross-sectional associations of plasma vitamin D with cerebral β-amyloid in older adults at risk of dementia,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0371-1
210,A biomarker study in long-lasting amnestic mild cognitive impairment,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0369-8
211,A language-based sum score for the course and therapeutic intervention in primary progressive aphasia,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0345-3
212,Lack of human-like extracellular sortilin neuropathology in transgenic Alzheimer’s disease model mice and macaques,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0370-2
213,Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0367-x
214,A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0368-9
215,The impact of group activities and their content on persons with dementia attending them,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0357-z
216,Representativeness of European clinical trial populations in mild Alzheimer’s disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0360-4
217,Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD),http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0366-y
218,Naming is not explaining: future directions for the “cognitive reserve” and “brain maintenance” theories,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0365-z
219,Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer’s disease dementia in mild cognitive impairment,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0362-2
220,Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0361-3
221,"Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0364-0
222,White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0359-x
223,Prospective associations between pulse pressure and cognitive performance in Chinese middle-aged and older population across a 5-year study period,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0355-1
224,The left frontal cortex supports reserve in aging by enhancing functional network efficiency,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0358-y
225,Improving the identification of dementia with Lewy bodies in the context of an Alzheimer’s-type dementia,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0356-0
226,"Thiamine diphosphate reduction strongly correlates with brain glucose hypometabolism in Alzheimer’s disease, whereas amyloid deposition does not",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0354-2
227,Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0353-3
228,"Amyloid β-induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0352-4
229,Disease-related determinants are associated with mortality in dementia due to Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0348-0
230,Genome-wide pleiotropy analysis of neuropathological traits related to Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0349-z
231,Effects of pharmacological and nonpharmacological treatments on brain functional magnetic resonance imaging in Alzheimer’s disease and mild cognitive impairment: a critical review,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0347-1
232,Clinical prevalence of Lewy body dementia,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0350-6
233,MH84 improves mitochondrial dysfunction in a mouse model of early Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0342-6
234,Associations of Bcl-2 rs956572 genotype groups in the structural covariance network in early-stage Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0344-4
235,Early brain connectivity alterations and cognitive impairment in a rat model of Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0346-2
236,Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE),http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0314-2
237,Impact of amyloid-beta changes on cognitive outcomes in Alzheimer’s disease: analysis of clinical trials using a quantitative systems pharmacology model,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0343-5
238,Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0341-7
239,"Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0340-8
240,Novel botanical drug DA-9803 prevents deficits in Alzheimer’s mouse models,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0338-2
241,Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer’s disease model,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0337-3
242,Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0336-4
243,A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-018-0339-1
244,Extended FTLD pedigree segregating a Belgian GRN-null mutation: neuropathological heterogeneity in one family,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0334-y
245,A novel language-neutral Visual Cognitive Assessment Test (VCAT): validation in four Southeast Asian countries,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0333-z
246,Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0335-x
247,Data-driven identification of endophenotypes of Alzheimer’s disease progression: implications for clinical trials and therapeutic interventions,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0332-0
248,The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0331-1
249,Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic review,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0330-2
250,Diffusion kurtosis imaging allows the early detection and longitudinal follow-up of amyloid-β-induced pathology,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0329-8
251,Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0328-9
252,A selenium species in cerebrospinal fluid predicts conversion to Alzheimer’s dementia in persons with mild cognitive impairment,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0323-1
253,Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0326-y
254,Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0324-0
255,Rho GTPases as therapeutic targets in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0320-4
256,"Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0325-z
257,A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0318-y
258,"Anemia is associated with incidence of dementia: a national health screening study in Korea involving 37,900 persons",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0322-2
259,Study partners should be required in preclinical Alzheimer’s disease trials,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0327-x
260,Amnestic MCI patients’ experiences after disclosure of their amyloid PET result in a research context,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0321-3
261,"Neurons derived from sporadic Alzheimer’s disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0317-z
262,The clinical significance of plasma clusterin and Aβ in the longitudinal follow-up of patients with Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0319-x
263,Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0316-0
264,Race modifies the relationship between cognition and Alzheimer’s disease cerebrospinal fluid biomarkers,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0315-1
265,The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0312-4
266,Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0313-3
267,Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ42,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0310-6
268,Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0301-7
269,PKR involvement in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0308-0
270,Gene suppression approaches to neurodegeneration,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0307-1
271,Attitudes toward clinical trials across the Alzheimer’s disease spectrum,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0311-5
272,N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0309-z
273,ERβ and ApoE isoforms interact to regulate BDNF–5-HT2A signaling and synaptic function in the female brain,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0305-3
274,Metabolic status of CSF distinguishes rats with tauopathy from controls,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0303-5
275,Tracking progressive pathological and functional decline in the rTg4510 mouse model of tauopathy,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0306-2
276,Serotonin 5-HT6 receptors affect cognition in a mouse model of Alzheimer’s disease by regulating cilia function,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0304-4
277,Personalized predictive modeling for patients with Alzheimer’s disease using an extension of Sullivan’s life table model,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0302-6
278,Serotonin augmentation therapy by escitalopram has minimal effects on amyloid-β levels in early-stage Alzheimer’s-like disease in mice,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0298-y
279,Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0299-x
280,Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0300-8
281,Alzheimer’s disease prevention: from risk factors to early intervention,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0297-z
282,Early- versus late-onset Alzheimer’s disease in clinical practice: cognitive and global outcomes over 3 years,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0294-2
283,Dietary arachidonic acid increases deleterious effects of amyloid-β oligomers on learning abilities and expression of AMPA receptors: putative role of the ACSL4-cPLA2 balance,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0295-1
284,Structured physical exercise improves neuropsychiatric symptoms in acute dementia care: a hospital-based RCT,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0289-z
285,Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0288-0
286,A coiled conformation of amyloid-β recognized by antibody C706,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0296-0
287,Cost of diagnosing dementia in a German memory clinic,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0290-6
288,Associations of thyroid hormone serum levels with in-vivo Alzheimer’s disease pathologies,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0291-5
289,Distinct white matter microstructural abnormalities and extracellular water increases relate to cognitive impairment in Alzheimer’s disease with and without cerebrovascular disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0292-4
290,Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0293-3
291,Can cognitive assessment really discriminate early stages of Alzheimer’s and behavioural variant frontotemporal dementia at initial clinical presentation?,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0287-1
292,On the path to 2025: understanding the Alzheimer’s disease continuum,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0283-5
293,"Association between chronic periodontitis and the risk of Alzheimer’s disease: a retrospective, population-based, matched-cohort study",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0282-6
294,Sensitivity of restriction spectrum imaging to memory and neuropathology in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0281-7
295,Risk of head and traumatic brain injuries associated with antidepressant use among community-dwelling persons with Alzheimer’s disease: a nationwide matched cohort study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0285-3
296,"Anticholinergic drugs and functional, cognitive impairment and behavioral disturbances in patients from a memory clinic with subjective cognitive decline or neurocognitive disorders",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0284-4
297,"Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0279-1
298,"Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0276-4
299,Increased Aβ42-α7-like nicotinic acetylcholine receptor complex level in lymphocytes is associated with apolipoprotein E4-driven Alzheimer’s disease pathogenesis,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0280-8
300,Behavioural and neuroanatomical correlates of auditory speech analysis in primary progressive aphasias,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0278-2
301,The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer’s disease: results from a randomized controlled trial,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0286-2
302,A novel Alzheimer’s disease drug candidate targeting inflammation and fatty acid metabolism,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0277-3
303,No added diagnostic value of non-phosphorylated tau fraction (p-taurel) in CSF as a biomarker for differential dementia diagnosis,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0275-5
304,"Cerebrospinal fluid biomarkers for Alzheimer's and vascular disease vary by age, gender, and APOE genotype in cognitively normal adults",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0271-9
305,Long-term cognitive outcome of Alzheimer’s disease and dementia with Lewy bodies: dual disease is worse,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0272-8
306,Oligomeric tau-targeted immunotherapy in Tg4510 mice,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0274-6
307,Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0273-7
308,"Digitally translated Self-Administered Gerocognitive Examination (eSAGE): relationship with its validated paper version, neuropsychological evaluations, and clinical assessments",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0269-3
309,"One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0270-x
310,Stem cell models of Alzheimer’s disease: progress and challenges,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0268-4
311,A vaccine with Aβ oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0267-5
312,"Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40)",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0265-7
313,Efficacy of the Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training (USMART) program among patients with mild cognitive impairment: a randomized controlled crossover trial,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0264-8
314,Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0266-6
315,Association between blood pressure and Alzheimer disease measured up to 27 years prior to diagnosis: the HUNT Study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0262-x
316,Optimizing medication appropriateness in older adults: a randomized clinical interventional trial to decrease anticholinergic burden,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0263-9
317,Communicating mild cognitive impairment diagnoses with and without amyloid imaging,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0261-y
318,Analyzing the genes related to Alzheimer’s disease via a network and pathway-based approach,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0252-z
319,Antipsychotic prescribing for Alzheimer’s disease and related disorders in specialized settings from 2010 to 2014 in France: a repeated cross-sectional study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0256-8
320,Memory is preserved in older adults taking AT1 receptor blockers,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0255-9
321,Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer’s disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0260-z
322,The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer’s pathology,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0258-6
323,Evaluation of a DNA Aβ42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA Aβ42 trimer,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0257-7
324,Multireceptor fingerprints in progressive supranuclear palsy,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0259-5
325,The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0254-x
326,"Perseverance time of informal caregivers for people with dementia: construct validity, responsiveness and predictive validity",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0251-0
327,"Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0253-y
328,Memory performance-related dynamic brain connectivity indicates pathological burden and genetic risk for Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0249-7
329,DHA brain uptake and APOE4 status: a PET study with [1-11C]-DHA,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0250-1
330,Structured relearning of activities of daily living in dementia: the randomized controlled REDALI-DEM trial on errorless learning,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0247-9
331,Predicting dementia using socio-demographic characteristics and the Free and Cued Selective Reminding Test in the general population,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0230-x
332,Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0248-8
333,Cognitive profile in prodromal dementia with Lewy bodies,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0242-1
334,Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0243-0
335,Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0245-y
336,Validating the role of the Australian National University Alzheimer’s Disease Risk Index (ANU-ADRI) and a genetic risk score in progression to cognitive impairment in a population-based cohort of older adults followed for 12 years,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0240-3
337,Evaluation of a research diagnostic algorithm for DSM-5 neurocognitive disorders in a population-based cohort of older adults,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0246-x
338,Role of neuroinflammation in neurodegeneration: new insights,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0241-2
339,Retinal vascular and structural changes are associated with amyloid burden in the elderly: ophthalmic biomarkers of preclinical Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0239-9
340,Erratum to: The societal costs of dementia in Sweden 2012 – relevance and methodological challenges in valuing informal care,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0244-z
341,Proportion of dementia in Australia explained by common modifiable risk factors,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0238-x
342,Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0237-y
343,The effects of different familial Alzheimer’s disease mutations on APP processing in vivo,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0234-1
344,Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0233-7
345,Increased dementia risk predominantly in diabetes mellitus rather than in hypertension or hyperlipidemia: a population-based cohort study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0236-z
346,Interaction between personality traits and cerebrospinal fluid biomarkers of Alzheimer’s disease pathology modulates cognitive performance,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-017-0235-0
347,Peripheral apoE isoform levels in cognitively normal APOE ε3/ε4 individuals are associated with regional gray matter volume and cerebral glucose metabolism,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0231-9
348,Sorting nexin-4 regulates β-amyloid production by modulating β-site-activating cleavage enzyme-1,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0232-8
349,A cognitive electrophysiological signature differentiates amnestic mild cognitive impairment from normal aging,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0229-3
350,Diagnostic impact of [18F]flutemetamol PET in early-onset dementia,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0228-4
351,Tau passive immunization inhibits not only tau but also Aβ pathology,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0227-5
352,"SORL1 gene, plasma biomarkers, and the risk of Alzheimer’s disease for the Han Chinese population in Taiwan",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0222-x
353,A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1–42 peptide in human plasma with utility for studies of Alzheimer’s disease therapeutics,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0225-7
354,Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0221-y
355,"LW-AFC, a new formula derived from Liuwei Dihuang decoction, ameliorates behavioral and pathological deterioration via modulating the neuroendocrine-immune system in PrP-hAβPPswe/PS1ΔE9 transgenic mice",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0226-6
356,Desire for predictive testing for Alzheimer’s disease and impact on advance care planning: a cross-sectional study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0223-9
357,Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0220-z
358,Brain activation in frontotemporal and Alzheimer’s dementia: a functional near-infrared spectroscopy study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0224-8
359,"An update on semantic dementia: genetics, imaging, and pathology",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0219-5
360,Changes in cerebral glucose metabolism after 3 weeks of noninvasive electrical stimulation of mild cognitive impairment patients,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0218-6
361,Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-β and tau pathology,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0217-7
362,Outcomes measures in a decade of dementia and mild cognitive impairment trials,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0216-8
363,The societal costs of dementia in Sweden 2012 – relevance and methodological challenges in valuing informal care,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0215-9
364,Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-controlled study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0214-x
365,"Psychological, behavioral and social effects of disclosing Alzheimer’s disease biomarkers to research participants: a systematic review",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0212-z
366,Using the Affiliate Stigma Scale with caregivers of people with dementia: psychometric evaluation,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0213-y
367,"ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0210-1
368,Identifying biomarkers of dementia prevalent among amnestic mild cognitively impaired ethnic female patients,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0211-0
369,Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0209-7
370,The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0208-8
371,Regional tau deposition measured by [18F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0204-z
372,Drug development in Alzheimer’s disease: the path to 2025,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0207-9
373,"Protective effect of melatonin on soluble Aβ1–42-induced memory impairment, astrogliosis, and synaptic dysfunction via the Musashi1/Notch1/Hes1 signaling pathway in the rat hippocampus",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0206-x
374,Alzheimer’s Research UK 2016 Conference report,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0203-0
375,A proposed preventive role for Gamma-hydroxybutyrate (XyremR) in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0205-y
376,Generation of a new transgenic mouse model for assessment of tau gene silencing therapies,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0202-1
377,Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0199-5
378,A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0200-3
379,Older patients are still under-represented in clinical trials of Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0201-2
380,Exploring anterograde memory: a volumetric MRI study in patients with mild cognitive impairment,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0190-1
381,"Recent global trends in the prevalence and incidence of dementia, and survival with dementia",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0188-8
382,Grey matter atrophy in prodromal stage of dementia with Lewy bodies and Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0198-6
383,Brain perfusion in dementia with Lewy bodies and Alzheimer’s disease: an arterial spin labeling MRI study on prodromal and mild dementia stages,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0196-8
384,Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer’s disease patients: application of a second-generation encapsulated cell biodelivery device,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0195-9
385,Retraction Note: Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0197-7
386,The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0194-x
387,Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0193-y
388,Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0192-z
389,High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0191-0
390,miRNA-dependent target regulation: functional characterization of single-nucleotide polymorphisms identified in genome-wide association studies of Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0186-x
391,Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0184-z
392,The algorithm for Alzheimer risk assessment based on APOE promoter polymorphisms,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0187-9
393,"Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0189-7
394,Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0182-1
395,Classification of the primary progressive aphasias: principles and review of progress since 2011,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0185-y
396,CRTC1 gene is differentially methylated in the human hippocampus in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0183-0
397,Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0181-2
398,"Transcranial direct current stimulation as a memory enhancer in patients with Alzheimer’s disease: a randomized, placebo-controlled trial",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0180-3
399,Cognitive and affective theory of mind in dementia with Lewy bodies and Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0179-9
400,A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0178-x
401,First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0177-y
402,Mini Mental State Examination and Logical Memory scores for entry into Alzheimer’s disease trials,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0176-z
403,Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0174-1
404,Alzheimer’s Disease Assessment Scale–Cognitive subscale variants in mild cognitive impairment and mild Alzheimer’s disease: change over time and the effect of enrichment strategies,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0170-5
405,Increased CSF tau level is correlated with decreased lamina cribrosa thickness,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0169-3
406,"Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer’s disease",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0173-2
407,An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0167-5
408,A longitudinal study of anxiety and cognitive decline in dementia with Lewy bodies and Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0171-4
409,Association between dental amalgam fillings and Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0175-0
410,Reference tissue normalization in longitudinal 18F-florbetapir positron emission tomography of late mild cognitive impairment,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-016-0172-3
411,Microstate connectivity alterations in patients with early Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0163-9
412,Conversion of mild cognitive impairment patients in Alzheimer’s disease: prognostic value of Alpha3/Alpha2 electroencephalographic rhythms power ratio,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0162-x
413,Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0164-8
414,Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0161-y
415,APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0160-z
416,Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0159-5
417,In vivo molecular neuroimaging of glucose utilization and its association with fibrillar amyloid-β load in aged APPPS1-21 mice,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0158-6
418,Role of ABCA7 loss-of-function variant in Alzheimer's disease: a replication study in European–Americans,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0154-x
419,Hippocampal atrophy but not white-matter changes predicts the long-term cognitive response to cholinesterase inhibitors in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0155-9
420,Alzheimer’s disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0157-7
421,"Central delivery of iodine-125–labeled cetuximab, etanercept and anakinra after perispinal injection in rats: possible implications for treating Alzheimer’s disease",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0149-7
422,Association between dental amalgam fillings and Alzheimer’s disease: a population-based cross-sectional study in Taiwan,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0150-1
423,New scoring methodology improves the sensitivity of the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0151-0
424,Improved predictive ability of the Montreal Cognitive Assessment for diagnosing dementia in a community-based study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0156-8
425,Predicting Alzheimer's disease development: a comparison of cognitive criteria and associated neuroimaging biomarkers,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0152-z
426,Compression or expansion of dementia in Germany? An observational study of short-term trends in incidence and death rates of dementia between 2006/07 and 2009/10 based on German health insurance data,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0146-x
427,The need for thorough phase II studies in medicines development for Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0153-y
428,Verbal and non-verbal memory and hippocampal volumes in a memory clinic population,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0147-9
429,Assessing clinicopathological correlation in chronic traumatic encephalopathy: rationale and methods for the UNITE study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0148-8
430,Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0145-y
431,The Third French Alzheimer Plan: analysis of the influence of a national public health initiative on scientific research productivity and impact,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0144-z
432,"Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0142-1
433,Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0143-0
434,Re-examining tau-immunoreactive pathology in the population: granulovacuolar degeneration and neurofibrillary tangles,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0141-2
435,Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0139-9
436,Modulation of Aβ42 in vivo by γ-secretase modulator in primates and humans,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0137-y
437,Frailty and the risk of cognitive impairment,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0140-3
438,An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0136-z
439,Report from the Alzheimer’s Research UK Conference 2015,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0138-x
440,Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0134-1
441,A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0135-0
442,Association of cognitive function with glucose tolerance and trajectories of glucose tolerance over 12 years in the AusDiab study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0131-4
443,Unraveling the potential co-contributions of cerebral small vessel vasculopathy to the pathogenesis of Alzheimer’s dementia,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0133-2
444,Diffusion imaging changes in grey matter in Alzheimer’s disease: a potential marker of early neurodegeneration,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0132-3
445,Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0124-3
446,Alzheimer’s disease progression by geographical region in a clinical trial setting,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0127-0
447,"Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0122-5
448,"The impact of diabetes on cognitive decline: potential vascular, metabolic, and psychosocial risk factors",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0130-5
449,Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0121-6
450,"Cumulative impact of health deficits, social vulnerabilities, and protective factors on cognitive dynamics in late life: a multistate modeling approach",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0120-7
451,Connectivity and circuitry in a dish versus in a brain,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0129-y
452,Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0114-5
453,Comprehensive treatment of dementia with Lewy bodies,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0128-z
454,"Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0109-2
455,Apolipoprotein E-dependent load of white matter hyperintensities in Alzheimer’s disease: a voxel-based lesion mapping study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0111-8
456,Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0112-7
457,"Brivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimer’s disease mouse model",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0110-9
458,Total testosterone and neuropsychiatric symptoms in elderly men with Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0107-4
459,Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0108-3
460,Post-mortem analysis of neuroinflammatory changes in human Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0126-1
461,RETRACTED ARTICLE: Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0102-9
462,The dynamics of monocytes and microglia in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0125-2
463,"A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0119-0
464,Alpha-synucleinopathy and neuropsychological symptoms in a population-based cohort of the elderly,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0101-x
465,HIV effects on age-associated neurocognitive dysfunction: premature cognitive aging or neurodegenerative disease?,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0123-4
466,The relationship of weight change trajectory with medial temporal lobe atrophy in patients with mild Alzheimer’s disease: results from a cohort study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0098-1
467,Linking a research register to clinical records in older adults’ mental health services: a mixed-methods study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0103-8
468,Is the risk of Alzheimer’s disease and dementia declining?,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0118-1
469,Co-morbidity and systemic inflammation as drivers of cognitive decline: new experimental models adopting a broader paradigm in dementia research,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0117-2
470,A highly sensitive novel immunoassay specifically detects low levels of soluble Aβ oligomers in human cerebrospinal fluid,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0100-y
471,Lung disease as a determinant of cognitive decline and dementia,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0116-3
472,Dementia trials and dementia tribulations: methodological and analytical challenges in dementia research,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0113-6
473,Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0099-0
474,Kidney disease as a determinant of cognitive decline and dementia,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0115-4
475,Changes in the neurochemistry of athletes with repetitive brain trauma: preliminary results using localized correlated spectroscopy,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0094-5
476,Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0088-8
477,"Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0093-y
478,"‘Hearts and minds’: association, causation and implication of cognitive impairment in heart failure",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0106-5
479,Clinical and imaging features of mixed Alzheimer and vascular pathologies,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0104-7
480,"Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0105-6
481,Neural correlates of visual hallucinations in dementia with Lewy bodies,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0091-0
482,The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0090-1
483,Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0081-2
484,"Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0083-0
485,Principles and management of neuropsychiatric symptoms in Alzheimer’s dementia,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0096-3
486,What we can learn from animal models about cerebral multi-morbidity,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0097-2
487,The cost-effectiveness challenge: is it worth it?,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-015-0095-4
488,Elevated cerebrovascular resistance index is associated with cognitive dysfunction in the very-old,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0080-3
489,Fitting the epidemiology and neuropathology of the early stages of Alzheimer’s disease to prevent dementia,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0079-9
490,Sensitivity to change and prediction of global change for the Alzheimer’s Questionnaire,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0092-z
491,BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0089-7
492,Imaging endpoints for clinical trials in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0087-9
493,Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0086-x
494,"Expression of one important chaperone protein, heat shock protein 27, in neurodegenerative diseases",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0078-x
495,Abnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimer’s disease using the Multiple Sleep Latency Test,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0076-z
496,Differentiating between visual hallucination-free dementia with Lewy bodies and corticobasal syndrome on the basis of neuropsychology and perfusion single-photon emission computed tomography,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0071-4
497,Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0077-y
498,Quantitative neuropathological assessment to investigate cerebral multi-morbidity,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0085-y
499,Applying a cumulative deficit model of frailty to dementia: progress and future challenges,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0084-z
500,BrainCheck - a very brief tool to detect incipient cognitive decline: optimized case-finding combining patient- and informant-based data,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0069-y
501,Prevalence of mixed pathologies in the aging brain,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0082-1
502,β-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid precursor protein cleavage,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0075-0
503,Transcranial magnetic stimulation and transcranial direct current stimulation: treatments for cognitive and neuropsychiatric symptoms in the neurodegenerative dementias?,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0074-1
504,PLD3 is accumulated on neuritic plaques in Alzheimer’s disease brains,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0070-5
505,Alpha-synuclein biology in Lewy body diseases,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0073-2
506,Study protocol: Randomised controlled trial to evaluate the impact of an educational programme on Alzheimer’s disease patients’ quality of life,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0066-1
507,Association between cell-bound blood amyloid-β(1 - 40) levels and hippocampus volume,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0056-3
508,Biomarkers in biological fluids for dementia with Lewy bodies,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0072-3
509,"Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCANTM) in subjects with clinically uncertain parkinsonian syndromes",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0067-0
510,Comorbidity profile in dementia with Lewy bodies versus Alzheimer’s disease: a linkage study between the Swedish Dementia Registry and the Swedish National Patient Registry,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0065-2
511,Clinical subtypes of chronic traumatic encephalopathy: literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0068-z
512,"Erratum to: Cardiovascular medication burden in dementia disorders: a nationwide study of 19, 743 dementia patients in the Swedish Dementia Registry",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0063-4
513,Age-related deficit accumulation and the risk of late-life dementia,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0054-5
514,A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0053-6
515,Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0061-6
516,Pro: Are we ready to translate Alzheimer's disease modifying therapies to people with Down syndrome?,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0060-7
517,Considerations for animal models of blast-related traumatic brain injury and chronic traumatic encephalopathy,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0064-3
518,"Imago Mundi, Imago AD, Imago ADNI",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0062-5
519,Moving beyond the pros and cons of automating cognitive testing in pathological aging and dementia: the case for equal opportunity,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0058-1
520,"Advocacy, education, and the role of not-for-profit organizations in Lewy body dementias",http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0059-0
521,Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an 11C altropane positron emission tomography study,http://alzres.biomedcentral.com/track/pdf/10.1186/s13195-014-0052-7
522,Treatment effects in multiple cognitive domains in Alzheimer’s disease: a two-year cohort study,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt280
523,"Subcortical hyperintensity volumetrics in Alzheimer’s disease and normal elderly in the Sunnybrook Dementia Study: correlations with atrophy, executive function, mental processing speed, and verbal memory",http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt279
524,Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt277
525,First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt278
526,Imaging as a biomarker in drug discovery for Alzheimer’s disease: is MRI a suitable technology?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt276
527,The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt275
528,The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt274
529,Differentially charged isoforms of apolipoprotein E from human blood are potential biomarkers of Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt273
530,Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt272
531,Cerebral inflammation is an underlying mechanism of early death in Alzheimer’s disease: a 13-year cause-specific multivariate mortality study,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt271
532,Basic to translational research in dementia: meeting report from the Alzheimer’s Research UK Conference 2014,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt270
533,"Alzheimer’s disease drug-development pipeline: few candidates, frequent failures",http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt269
534,Association of MAPT haplotypes with Alzheimer’s disease risk and MAPT brain gene expression levels,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt268
535,A diagnostic scale for Alzheimer’s disease based on cerebrospinal fluid biomarker profiles,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt267
536,Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt266
537,Dietary regulation of PI3K/AKT/GSK-3β pathway in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt265
538,"Cardiovascular medication burden in dementia disorders: a nationwide study of 19,743 dementia patients in the Swedish Dementia Registry",http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt264
539,Cerebral microbleeds: overview and implications in cognitive impairment,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt263
540,β-amyloid deposition is shifted to the vasculature and memory impairment is exacerbated when hyperhomocysteinemia is induced in APP/PS1 transgenic mice,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt262
541,Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt261
542,PERK: a novel therapeutic target for neurodegenerative diseases?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt260
543,Acetylation: a new key to unlock tau’s role in neurodegeneration,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt259
544,Truncated and modified amyloid-beta species,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt258
545,The association of angiotensin-converting enzyme with biomarkers for Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt257
546,A coimmunization vaccine of Aβ42 ameliorates cognitive deficits without brain inflammation in an Alzheimer’s disease model,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt256
547,Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt255
548,Is pathological aging a successful resistance against amyloid-beta or preclinical Alzheimer’s disease?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt254
549,Roadblocks for integration of novel biomarker concepts into clinical routine: the peptoid approach,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt253
550,Meeting report on the Alzheimer’s Drug Discovery Foundation 14th International Conference on Alzheimer’s Drug Discovery,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt252
551,Lewy body dementia: the impact on patients and caregivers,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt251
552,Performance on a pattern separation task by Alzheimer’s patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E ∈4 status and cerebrospinal fluid amyloid-β42 levels,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt250
553,Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt249
554,Neuroimaging characteristics of dementia with Lewy bodies,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt248
555,TMEM106B expression is reduced in Alzheimer’s disease brains,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt247
556,Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt246
557,Platelet-activating factor antagonists enhance intracellular degradation of amyloid-β42 in neurons via regulation of cholesterol ester hydrolases,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt245
558,Interpreting Alzheimer’s disease clinical trials in light of the effects on amyloid-β,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt244
559,Protein recycling pathways in neurodegenerative diseases,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt243
560,A controlled trial of Partners in Dementia Care: veteran outcomes after six and twelve months,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt242
561,Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt241
562,Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt240
563,Neuroimaging in repetitive brain trauma,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt239
564,Fyn kinase inhibition as a novel therapy for Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt238
565,Active immunotherapy options for Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt237
566,Amyloid-beta 42 adsorption following serial tube transfer,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt236
567,Circulating biomarkers that predict incident dementia,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt235
568,Chronic traumatic encephalopathy: a spectrum of neuropathological changes following repetitive brain trauma in athletes and military personnel,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt234
569,Open questions for Alzheimer’s disease immunotherapy,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt233
570,Photobiomodulation with near infrared light mitigates Alzheimer’s disease-related pathology in cerebral cortex – evidence from two transgenic mouse models,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt232
571,Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt231
572,Adjusting the compass: new insights into the role of angiogenesis in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt230
573,Rivastigmine in moderately severe-to-severe Alzheimer’s disease: Severe Impairment Battery factor analysis,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt229
574,Should interventions to treat or prevent Alzheimer’s disease be tested in a population or as targeted treatment of highly selected study participants?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt228
575,Protein quality control by Rer1p in the early secretory pathway: from mechanism to implication in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt227
576,Amyloid β-protein oligomers and Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt226
577,Nanoparticulate flurbiprofen reduces amyloid-β42 generation in an in vitro blood–brain barrier model,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt225
578,"The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer’s disease",http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt224
579,Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt223
580,Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer’s disease: a selective review,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt222
581,High adiposity: risk factor for dementia and Alzheimer’s disease?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt221
582,Treating Alzheimer’s disease with monoclonal antibodies: current status and outlook for the future,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt220
583,Calmodulin levels in blood cells as a potential biomarker of Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt219
584,When the dust settles: what did we learn from the bexarotene discussion?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt218
585,Autophagic/lysosomal dysfunction in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt217
586,Predictors of decline in walking ability in community-dwelling Alzheimer’s disease patients: Results from the 4-years prospective REAL.FR study,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt216
587,Neuroprotective effects of donepezil against cholinergic depletion,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt215
588,Propagation of tau pathology in Alzheimer’s disease: identification of novel therapeutic targets,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt214
589,Dominantly Inherited Alzheimer Network: facilitating research and clinical trials,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt213
590,"Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples",http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt212
591,The role of APP and BACE1 trafficking in APP processing and amyloid-β generation,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt211
592,Progression of mild Alzheimer’s disease: knowledge and prediction models required for future treatment strategies,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt210
593,Progress in novel cognitive enhancers for cognitive aging and Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt209
594,Diets involved in PPAR and PI3K/AKT/PTEN pathway may contribute toneuroprotection in a traumatic brain injury,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt208
595,Potential synergy between tau aggregation inhibitors and tau chaperonemodulators,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt207
596,Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt206
597,Importance of national plans for Alzheimer’s disease and dementia,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt205
598,Apolipoprotein E as a β-amyloid-independent factor in Alzheimer’s disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt204
599,On the subject of rigor in the study of amyloid β-protein assembly,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt203
600,Amyloid imaging in clinical trials,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt195
601,Regulation of distinct pools of amyloid β-protein by multiple cellular proteases,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt194
602,Cognitive training and cognitive rehabilitation for persons with mild to moderate dementia of the Alzheimer's or vascular type: a review,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt189
603,Early-onset dementias: diagnostic and etiological considerations,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt197
604,Epidemiology of neurodegeneration in American-style professional football players,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt188
605,Evidence for impaired amyloid β clearance in Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt187
606,A survey of TREM2 antibodies reveals neuronal but not microglial staining in formalin-fixed paraffin-embedded postmortem Alzheimer's brain tissues,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt184
607,Knowledge translation: an overview and recommendations in relation to the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt202
608,Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt201
609,Role of emerging neuroimaging modalities in patients with cognitive impairment: a review from the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt200
610,Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt199
611,Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt198
612,Diagnosis and Treatment of Dementia: the Fourth Canadian Consensus Conference,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt196
613,Dementia in the oldest old: a multi-factorial and growing public health issue,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt181
614,Multiplex biomarkers in blood,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt185
615,Modeling the course of Alzheimer's disease to improve clinical trials: symposium report,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt183
616,Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt186
617,What boxing tells us about repetitive head trauma and the brain,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt177
618,Progress in Alzheimer's disease research circa 2013: Is the glass half empty or half full?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt180
619,Comprehensive behavioral characterization of an APP/PS-1 double knock-in mouse model of Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt182
620,Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt178
621,Separation of cognitive domains to improve prediction of progression from mild cognitive impairment to Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt176
622,The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt179
623,Advances in blood-based protein biomarkers for Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt172
624,Modeling Alzheimer's disease with non-transgenic rat models,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt171
625,Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt175
626,5-HT6 receptors and Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt169
627,Neuroprotective effects of D-Ala2GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt174
628,"Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models",http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt173
629,DNA-dependent protein kinase and DNA repair: relevance to Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt167
630,The effect of cyclodextrin-solubilized curcuminoids on amyloid plaques in Alzheimer transgenic mice: brain uptake and metabolism after intravenous and subcutaneous injection,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt170
631,Plasma tau levels in Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt163
632,Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt165
633,Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt162
634,"Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems",http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt164
635,Modeling the heterogeneity in risk of progression to Alzheimer's disease acrosscognitive profiles in mild cognitive impairment,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt168
636,Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt166
637,The C9ORF72 mutation brings more answers and more questions,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt161
638,Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt159
639,Alcohol-related dementia: an update of the evidence,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt157
640,Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt160
641,18F-florbetaben Aβ imaging in mild cognitive impairment,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt158
642,"Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome",http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt155
643,Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt156
644,Assessment of psychiatric changes in C9ORF72 frontotemporal dementia,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt152
645,Does a prion-like mechanism play a major role in the apparent spread of α-synuclein pathology?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt151
646,"Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study",http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt154
647,"NF-κB-regulated, proinflammatory miRNAs in Alzheimer's disease",http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt150
648,Treatment implications of C9ORF72,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt149
649,Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt153
650,Neuroimaging features of C9ORF72 expansion,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt148
651,Stem cell models of Alzheimer's disease and related neurological disorders,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt147
652,"Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study",http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt146
653,Potential sources of interference on Abeta immunoassays in biological samples,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt142
654,Neuropsychiatric features of C9orf72-associated behavioral variant frontotemporal dementia and frontotemporal dementia with motor neuron disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt141
655,C9orf72 immunohistochemistry in Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt140
656,Longitudinal neuroimaging and neuropsychological profiles of frontotemporal dementia with C9ORF72 expansions,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt144
657,Dementia: a global health priority - highlights from an ADI and World Health Organization report,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt143
658,Championing of dementia in England,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt139
659,Alzheimer's disease diagnostic criteria: practical applications,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt138
660,"Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease",http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt135
661,"Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort",http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt137
662,Dystrophic neurites express C9orf72 in Alzheimer's disease brains,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt136
663,Impaired self-other differentiation in frontotemporal dementia due to the C9ORF72 expansion,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt145
664,Con: Alzheimer's disease and circadian dysfunction: chicken or egg?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt129
665,Pro: Alzheimer's disease and circadian dysfunction: chicken or egg?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt128
666,Increased expression of the homologue of enhancer-of-split 1 protects neurons from beta amyloid neurotoxicity and hints at an alternative role for transforming growth factor beta1 as a neuroprotector,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt134
667,Expanding the genetics of amyotrophic lateral sclerosis and frontotemporal dementia,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt133
668,Cognitive and behavioral features of c9FTD/ALS,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt132
669,Genetic counseling for FTD/ALS caused by the C9ORF72 hexanucleotide expansion,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt130
670,Measuring clinical progression in MCI and pre-MCI populations: enrichment and optimizing clinical outcomes over time,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt127
671,Systematic reviews on behavioural and psychological symptoms in the older or demented population,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt131
672,Supporting clinical research in the NHS in England: the National Institute for Health Research Dementias and Neurodegenerative Diseases Research Network,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt126
673,Ayurvedic medicinal plants for Alzheimer's disease: a review,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt125
674,Age-related increase in amyloid plaque burden is associated with impairment in conditioned fear memory in CRND8 mouse model of amyloidosis,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt124
675,Phenotypic differences between apolipoprotein E genetic subgroups: research and clinical implications,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt123
676,"Whether, when and how chronic inflammation increases the risk of developing late-onset Alzheimer's disease",http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt118
677,Resistant to amyloid-β or just waiting for disease to happen?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt122
678,Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt121
679,Recent Alzheimer's disease research highlights,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt117
680,Factors that influence survival in a probable Alzheimer disease cohort,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt119
681,Long-term benefit from deep brain stimulation of the subthalamic nucleus: is it for everyone?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt111
682,Examining the mechanisms that link β-amyloid and α-synuclein pathologies,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt109
683,"Reduction of low-density lipoprotein receptor-related protein (LRP1) in hippocampal neurons does not proportionately reduce, or otherwise alter, amyloid deposition in APPswe/PS1dE9 transgenic mice",http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt110
684,Relationships between the amyloid precursor protein and its various proteolytic fragments and neuronal systems,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt108
685,Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt107
686,Resting-state fMRI as a biomarker for Alzheimer's disease?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt106
687,"Cognitive reserve, cortical plasticity and resistance to Alzheimer's disease",http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt105
688,Dementia prevention: current epidemiological evidence and future perspective,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt104
689,Lipidomics of Alzheimer's disease: current status,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt103
690,Progranulin axis and recent developments in frontotemporal lobar degeneration,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt102
691,Statins and therapy of Alzheimer's disease: questions of efficacy versus trial design,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt101
692,Resting state functional MRI in Alzheimer's Disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt100
693,Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt98
694,Beyond amyloid: a diverse portfolio of novel drug discovery programs for Alzheimer's disease and related dementias,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt99
695,Patient self-report for evaluating mild cognitive impairment and prodromal Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt97
696,Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt96
697,Predicting Alzheimer's risk: why and how?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt95
698,A web-based normative calculator for the uniform data set (UDS) neuropsychological test battery,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt94
699,Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt93
700,Progress in understanding variability in cognitive responses to cholinesterase inhibitor treatment,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt92
701,Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt90
702,Defining and describing the pre-dementia stages of familial Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt91
703,Amyloid imaging in prodromal Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt88
704,Validation of the relevant outcome scale for Alzheimer's disease: a novel multidomain assessment for daily medical practice,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt89
705,Technical aspects of amyloid imaging for Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt87
706,Globalization of Alzheimer's disease clinical trials,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt86
707,Predictors of long-term cognitive outcome in Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt85
708,Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt83
709,Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt84
710,The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt82
711,Should persons with autosomal dominant AD be included in clinical trials? Authors' response,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt81
712,Should persons with autosomal dominant AD be included in clinical trials?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt80
713,Right sizing funding for Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt76
714,Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-β toxicity,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt74
715,"Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial",http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt75
716,What can we learn from study of Alzheimer's disease in patients with Down syndrome for early-onset Alzheimer's disease in the general population?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt72
717,Investigational drugs for the treatment of AD: what can we learn from negative trials?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt73
718,"CLU, CR1 and PICALM genes associate with Alzheimer's-related senile plaques",http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt71
719,PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt70
720,"Requiring an amyloid-β1-42 biomarker may improve the efficiency of a study, and simulations may help in planning studies",http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt69
721,For debate: substituting placebo controls in long-term Alzheimer's prevention trials,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt68
722,Stem cell factor and granulocyte colony-stimulating factor reduce β-amyloid deposits in the brains of APP/PS1 transgenic mice,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt67
723,Selectivity to amyloid-β precursor protein cleavage provides hope against Alzheimer's,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt66
724,Can aerobic exercise protect against dementia?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt65
725,Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational study,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt64
726,Should EOAD patients be included in clinical trials?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt63
727,Amyloid imaging and memory change for prediction of cognitive impairment,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt62
728,What was lost in translation in the DHA trial is whom you should intend to treat,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt61
729,Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt59
730,Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt60
731,Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt58
732,"A diverse portfolio of novel drug discovery efforts for Alzheimer's disease: Meeting report from the 11th International Conference on Alzheimer's Drug Discovery, 27-28 September 2010, Jersey City, NJ, USA",http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt57
733,Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt56
734,Prevention of Alzheimer's disease in high risk groups: statin therapy in subjects with PSEN1 mutations or heterozygosity for apolipoprotein E epsilon 4,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt55
735,Herbal therapy: a new pathway for the treatment of Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt54
736,A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt53
737,Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt52
738,Obesity and the brain: a possible genetic link,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt51
739,From model system to clinical medicine: pathophysiologic links of common proteinopathies,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt50
740,Dimebon disappointment,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt49
741,Role of structural MRI in Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt47
742,Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt48
743,The role of animal models in advancing amyloid-beta immunotherapy to the clinic,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt46
744,The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt36
745,Advances in quantitative magnetic resonance imaging-based biomarkers for Alzheimer disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt45
746,Mild traumatic brain injury: a risk factor for neurodegeneration,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt42
747,Pro: Can biomarkers be gold standards in Alzheimer's disease?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt41
748,Con: Can biomarkers be gold standards in Alzheimer's disease?,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt40
749,Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease,http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt44
750,"Vascular health, diabetes, APOE and dementia: the Aging, Demographics, and Memory Study",http://alzres.biomedcentral.com/track/pdf/10.1186/alzrt43
